Does Intravenous Cannabis Reduce Postoperative Nausea and Vomiting (PONV)?
NCT ID: NCT00695487
Last Updated: 2014-03-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
320 participants
INTERVENTIONAL
2008-07-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cannabidiol Oil Extract for Prevention of Postoperative Nausea and Vomiting
NCT06137027
Efficacy of Low Dose Promethazine for Postoperative Nausea and Vomiting
NCT01159548
Prevention of Intraoperative Nausea and Vomiting During Cesarean Section
NCT01216410
Prevention of Post-Operative Nausea and Vomiting With Propofol Infusion
NCT05759481
Continuous Infusion of Palonosetron for Preventing of Postoperative Nausea and Vomiting
NCT01482468
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Receives 0.125mg/kg THC before emergence
THC 9-d-tetra hydro cannabinol
0.125mg/kg iv one time
2
Receives NaCl before emergence
THC 9-d-tetra hydro cannabinol
0.125mg/kg iv one time
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
THC 9-d-tetra hydro cannabinol
0.125mg/kg iv one time
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* elective open and laparoscopic surgery \>1hour
Exclusion Criteria
* pregnancy, breast feeding
* \>ASA III
* BMI \>35
* antipsychotic, antiemetic, cytostatic therapy
* major cardiovascular, renal, hepatic, central nervous system disease
* current chronic cannabis consumption and hard drug abuse
* schizophrenia
* preoperative nausea and vomiting, vestibular disease
* not speaking german or french
* refusal to participate
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Insel Gruppe AG, University Hospital Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Greif, MD
Role: STUDY_DIRECTOR
Department of Anesthesia, Bern University Hospital , Switzerland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Inselspital, Bern University Hospital
Bern, Canton of Bern, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
THC-001
Identifier Type: -
Identifier Source: secondary_id
KEK240_07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.